公开(公告)号：WO1996038174A1

公开(公告)日：1996-12-05

申请号：PCT/US1996008250

申请日：1996-05-31

Applicant: OCULEX PHARMACEUTICALS, INC. ,  KOCHINKE, Frank ,  WONG, Vernon

Inventor： OCULEX PHARMACEUTICALS, INC.

IPC: A61K47/34

CPC classification number: A61K9/2054 ,  A61F9/0017 ,  A61F2210/0004 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/2013 ,  A61K9/204 ,  A61K47/34 ,  Y10S514/953

Abstract: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.

Abstract translation: 显示可生物降解的持续释放植入物中的亲水和疏水实体的组合来调节彼此的释放速率。 治疗活性剂和调节剂的制剂在延长的时间段内提供基本恒定的释放速率。

公开(公告)号：WO1995013765A1

公开(公告)日：1995-05-26

申请号：PCT/US1994012898

申请日：1994-11-09

Applicant: OCULEX PHARMACEUTICALS, INC.

Inventor： OCULEX PHARMACEUTICALS, INC. ,  WONG, Vernon, G. ,  KOCHINKE, Frank

IPC: A61F02/14

CPC classification number: A61F9/0017 ,  A61K9/0051

Abstract: Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Abstract translation: 为了治疗目的，包含活性剂的植入物被用于引入到脉管外空间或眼睛的无血管区域中。 药物的管理长期控制和维持，同时确保在管理现场之外实质上没有显着的水平。

公开(公告)号：WO1995003009A1

公开(公告)日：1995-02-02

申请号：PCT/US1994007721

申请日：1994-07-14

Applicant: OCULEX PHARMACEUTICALS, INC.

Inventor： OCULEX PHARMACEUTICALS, INC. ,  WONG, Vernon ,  LEE, King ,  GIN, Jerry, B.

IPC: A61F02/00

CPC classification number: A61K38/212 ,  A61K9/0048 ,  A61K9/1647

Abstract: Intraocular administration of drugs such as alpha -2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with systemic administration, concentrates the drug at the site of the disease, and, where microcapsules are employed, provides continuous, long-lasting treatment.

Abstract translation: 药物如α-2a干扰素的眼内给药用于治疗年龄相关性黄斑变性。 眼内给药消除与全身给药相关的副作用，将药物浓集在疾病部位，并且在使用微胶囊的地方提供连续的持久治疗。